OHIO STATE UNIVERSITY COLUMBUS, Ohio – The parasites that cause a disfiguring skin disease affecting about 12 million people globally may have met their match in vaccines developed using CRISPR gene-editing technology, new research suggests. Phase 1 human trials are set to start later this year with a vaccine designed to prevent infection by Leishmania major, the...